Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 13 tags : Phase 2 save search
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
Published: 2021-10-13 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -0.18%
H: 0.0%
C: 0.0%
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: 0.54%
H: 0.59%
C: -2.15%
phase 2 cancer vaccine pancreatic pancreas enroll
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s DiseaseThe Company anticipates topline data in the second half of 2022
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
AVXL | $3.8 -6.63% -7.11% 1.7M
|
Health Technology
|
| O: 0.17%
H: 3.65%
C: 2.32%
disease alzheimer phase 2 topline life science phase 2b trial anavex®2-73 anavex alzheimer’s alzheimer's
NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19
Published: 2021-10-13 (Crawled : 13:00) - biospace.com/
NRBO | $3.425 -1.01% -1.02% 23K
|
Health Technology
|
| O: 8.7%
H: 10.0%
C: -2.0%
covid phase 2 phase 2/3 positive trial
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0672 178.69% 100
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.77%
stroke phase 1 phase 2
Vera Therapeutics to Present Phase 2a Data on Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2021 Annual Meeting
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
VERA | $39.51 -1.25% -1.27% 860K
|
Professional, Scientific, and T...
|
| O: -2.26%
H: 6.94%
C: 1.91%
phase 2 nephropathy kidney phase 2b
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
Published: 2021-10-13 (Crawled : 07:00) - globenewswire.com
VRNA | $16.1 -1.83% -1.86% 490K
|
Health Technology
|
| O: 1.32%
H: 6.97%
C: 5.88%
phase 2 pharma
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.